Skip to main content

Hematology: Multiple Myeloma: Treatment with Bisphosphonates

CBE ID
0380
1.4 Project
Cancer
Endorsement Status
Endorsement Removed
1.1 New or Maintenance
Maintenance
Previous Endorsement Cycle
Fall 2017
Is Under Review
No
1.3 Measure Description

Percentage of patients aged 18 years and older with a diagnosis of multiple myeloma, not in remission, who were prescribed or received intravenous bisphosphonate therapy within the 12 month reporting period

    • 1.14 Numerator

      Patients who were prescribed or received intravenous bisphosphonate therapy within the 12 month reporting period

    • 1.15 Denominator

      All patients aged 18 years and older with a diagnosis of multiple myeloma, not in remission

    • Exclusions

      For Claims/Registry:
      Documentation of medical reason(s) for not prescribing bisphosphonates (eg, patients who do not have bone disease, patients with dental disease, patients with renal insufficiency)

      Documentation of patient reason(s) for not prescribing bisphosphonates

    • Most Recent Endorsement Activity
      Measure Retired and Endorsement Removed Cancer Fall Cycle 2017
      Initial Endorsement
      Last Updated
      Removal Date
    • Steward
      American Society of Hematology
      Steward Organization POC Email
      [email protected]